These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 28940301)

  • 21. Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Mijwel S; Backman M; Bolam KA; Jervaeus A; Sundberg CJ; Margolin S; Browall M; Rundqvist H; Wengström Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):79-93. PubMed ID: 29139007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Study of Yoga for Fatigue and Quality of Life in Women with Breast Cancer Undergoing (Neo) Adjuvant Chemotherapy.
    Jong MC; Boers I; Schouten van der Velden AP; Meij SV; Göker E; Timmer-Bonte ANJH; van Wietmarschen HA
    J Altern Complement Med; 2018; 24(9-10):942-953. PubMed ID: 30247961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: results of a feasibility intervention study.
    Berger AM; VonEssen S; Kuhn BR; Piper BF; Agrawal S; Lynch JC; Higginbotham P
    Oncol Nurs Forum; 2003; 30(3):513-22. PubMed ID: 12719750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy.
    Liu L; Mills PJ; Rissling M; Fiorentino L; Natarajan L; Dimsdale JE; Sadler GR; Parker BA; Ancoli-Israel S
    Brain Behav Immun; 2012 Jul; 26(5):706-13. PubMed ID: 22406004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
    Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
    Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
    Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial.
    van Waart H; Stuiver MM; van Harten WH; Geleijn E; Kieffer JM; Buffart LM; de Maaker-Berkhof M; Boven E; Schrama J; Geenen MM; Meerum Terwogt JM; van Bochove A; Lustig V; van den Heiligenberg SM; Smorenburg CH; Hellendoorn-van Vreeswijk JA; Sonke GS; Aaronson NK
    J Clin Oncol; 2015 Jun; 33(17):1918-27. PubMed ID: 25918291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer.
    Ratcliff CG; Lam CY; Arun B; Valero V; Cohen L
    Psychooncology; 2014 Nov; 23(11):1220-8. PubMed ID: 24706506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
    Ejlertsen B; Tuxen MK; Jakobsen EH; Jensen MB; Knoop AS; Højris I; Ewertz M; Balslev E; Danø H; Vestlev PM; Kenholm J; Nielsen DL; Bechmann T; Andersson M; Cold S; Nielsen HM; Maae E; Carlsen D; Mouridsen HT
    J Clin Oncol; 2017 Aug; 35(23):2639-2646. PubMed ID: 28661759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study.
    Dhanraj KM; Dubashi B; Gollapalli S; Kayal S; Cyriac SL
    Med Oncol; 2015 Dec; 32(12):261. PubMed ID: 26520144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
    J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer.
    Kuo HH; Chiu MJ; Liao WC; Hwang SL
    J Formos Med Assoc; 2006 Jan; 105(1):64-9. PubMed ID: 16440072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
    Boér K; Láng I; Juhos E; Pintér T; Szántó J
    Magy Onkol; 2003; 47(2):141-8. PubMed ID: 12975660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens.
    Berger AM; Lockhart K; Agrawal S
    Oncol Nurs Forum; 2009 Sep; 36(5):563-70. PubMed ID: 19726396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.